Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPG), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) generates frequent news flow as a global, commercial‑stage biopharmaceutical company focused on oncology. News coverage for AAPG centers on clinical trial data, regulatory milestones, commercialization updates in China, and strategic collaborations related to its portfolio of apoptotic pathway inhibitors and next‑generation kinase inhibitors.
Investors following AAPG news can expect regular updates on olverembatinib, the first novel third‑generation BCR‑ABL1 inhibitor approved in China for multiple drug‑resistant CML indications and covered by the China National Reimbursement Drug List. Recent announcements have highlighted four‑year follow‑up data in TKI‑resistant/intolerant CML‑CP, updated results in second‑line CML‑CP, and the first dataset from the global registrational Phase III POLARIS‑1 study in newly diagnosed Ph+ ALL, as well as regulatory clearances from the U.S. FDA and EMA for global Phase III trials.
News items also focus on Lisaftoclax, Ascentage Pharma’s Bcl‑2 selective inhibitor. Disclosures include pivotal China registrational Phase II data in BTK‑refractory relapsed/refractory CLL/SLL supporting NMPA approval, Phase Ib/II results in myeloid malignancies including venetoclax‑exposed patients, and global Phase III plans in CLL/SLL, AML, and HR MDS. Additional coverage addresses early‑stage programs such as the BTK degrader APG‑3288, which has received IND clearance from the U.S. FDA for a global Phase I study.
Beyond clinical data, AAPG news includes participation in major scientific and investor conferences, such as the American Society of Hematology (ASH) Annual Meeting and the J.P. Morgan Healthcare Conference, as well as investor webcasts and interim business updates furnished via Form 6‑K filings. This news page helps readers track how Ascentage Pharma advances its oncology pipeline, secures regulatory clearances, and expands commercialization of its hematology products.
Ascentage Pharma (NASDAQ: AAPG) announced the inclusion of two proprietary drugs in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax, their novel oral Bcl-2 selective inhibitor, received its first CSCO recommendation for treating relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It is the world's second Bcl-2 inhibitor to submit a New Drug Application and the first China-developed one to receive Priority Review.
Olverembatinib, their next-generation tyrosine kinase inhibitor, received an upgraded recommendation to Level I for treating children with Ph+ ALL harboring the T315I BCR-ABL1 mutation. The drug retained its recommendations in other CSCO Guidelines for various CML treatments. Notably, olverembatinib is included in China's National Reimbursement Drug List and is being jointly commercialized with Innovent Biologics.
Ascentage Pharma (NASDAQ: AAPG) reported strong financial results for 2024, with revenue surging 342% year-over-year to US$134.3 million, driven by a US$100 million Takeda option payment and robust olverembatinib sales growth of 52% to US$33.0 million in China.
Key developments include the successful completion of a US$132.5 million IPO on Nasdaq in January 2025 and lisaftoclax's NDA acceptance with Priority Review in China. The company is currently conducting ten registrational trials, including two FDA-cleared studies.
Financial highlights show reduced losses of US$55.6 million (down 56.2% YoY) and increased cash position of US$172.8 million (up 15.3%). Research and development expenses rose 34% to US$129.8 million, while selling and administrative expenses remained relatively stable.
Ascentage Pharma (NASDAQ: AAPG) has announced the presentation of five preclinical studies at the upcoming 2025 American Association of Cancer Research (AACR) Annual Meeting in Chicago. The presentations will showcase results from their innovative pipeline including:
- Olverembatinib combined with lisaftoclax for overcoming venetoclax resistance in acute myeloid leukemia (AML)
- Combination therapy effects in T-cell acute lymphoblastic leukemia (T-ALL)
- APG-5918's antitumor activity in prostate cancer models
- APG-2449's enhancement of chemotherapy in small-cell lung cancer
- AS03157 as an IAP antagonist
The presentations are scheduled between April 27-29, 2025, covering various experimental and molecular therapeutics sessions.
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company focused on developing therapies for hematological malignancies, has scheduled its full year 2024 financial results announcement and corporate update for March 27, 2025.
The company will host two investor events: an English conference call and webcast at 8:00 am EDT/8:00 pm HKT on March 27, and a Chinese (Mandarin) investor event at 9:30 am HKT on March 28. Both events will include Q&A sessions with management and will be available for replay on the company's website for 30 days.
Ascentage Pharma (NASDAQ: AAPG) announced that its drug olverembatinib received its third Breakthrough Therapy Designation (BTD) from China's NMPA for combination with low-intensity chemotherapy in treating newly-diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients.
This milestone follows previous BTDs granted in March 2021 for chronic-phase chronic myeloid leukemia and June 2023 for SDH-deficient gastrointestinal stromal tumor treatment. The BTD status prioritizes development and review processes, potentially enabling Priority Review and conditional approvals.
Ph+ ALL represents 20-30% of adult ALL cases in China, with an incidence rate of 0.69/100,000. Olverembatinib, China's first approved third-generation BCR-ABL inhibitor, is currently included in China's National Reimbursement Drug List for existing indications. A global Phase III study comparing olverembatinib plus chemotherapy versus imatinib plus chemotherapy in naïve Ph+ ALL patients was cleared in July 2023.
Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced that underwriters of its U.S. initial public offering have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (ADSs) at $17.25 per ADS. Each ADS represents four ordinary shares of the company.
Following this partial exercise, the total number of ADSs sold in the offering will increase to 8,260,144, bringing the aggregate gross proceeds to approximately $142.5 million, before deducting underwriting discounts, commissions, and other offering expenses. J.P. Morgan and Citigroup served as joint book-running managers for the offering.
Ascentage Pharma (Nasdaq: AAPG) has successfully completed its U.S. initial public offering, raising approximately $126.4 million in gross proceeds. The company offered 7,325,000 American depositary shares (ADSs) at $17.25 per ADS, with each ADS representing four ordinary shares. Trading of the ADSs commenced on the Nasdaq Global Market on January 24, 2025.
The company has granted underwriters a 30-day option to purchase up to an additional 1,098,750 ADSs at the initial offering price, less underwriting discounts and commissions. J.P. Morgan and Citigroup served as joint book-running managers for the offering.